Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Yahoo! Finance
25, Raymond James increased the price target on Dyne Therapeutics, Inc. (NASDAQ:DYN) stock from $31 to $35, maintaining its Buy rating. Martin Auster from Raymond James upgraded the price target on DYN as he remains optimistic on the upcoming DYNE-251 registrational cohort readout expected in late 2025. Auster sees potential in the upcoming investigational exon-skipping therapy for Duchenne Muscular Dystrophy (DMD). The company expects a Biologics License Application (BLA) filing in early 2026. The analyst's confidence is based on three major factors, including the differentiated profile of DYNE-251 compared to Exondys 51, a competing therapy in the DMD treatment space. Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating On August 4, Dyne Therapeutics announced the FDA approval for the treatment of patients with DMD. Auster believes in a pathway to accelerated approval for the therapy, which could boost its market entry if successful in cl
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
DYN
Earnings
- 5/8/25 - Miss
DYN
Sec Filings
- 12/5/25 - Form 144
- 12/5/25 - Form 144
- 12/5/25 - Form 4
- DYN's page on the SEC website